PhaseBio Pharmaceuticals Inc
PhaseBio Pharmaceuticals Inc (PHAS): 2 pipeline candidates · ~3 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.6 months
D/E -1.19 · 0% dilution
Lead: Phase 3
2 candidates
N/A
N/A
A transparent, data-derived signal for PhaseBio Pharmaceuticals Incacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$7.8M
Quarterly Burn
$10.4M
Runway
2.6 mo
Revenue
$208K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| bentracimab | Phase 3 |
| pb6440 | Preclinical |
Frequently asked questions
How many drug candidates are in PhaseBio Pharmaceuticals Inc's pipeline?
PhaseBio Pharmaceuticals Inc (PHAS) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PhaseBio Pharmaceuticals Inc's lead drug candidate?
PhaseBio Pharmaceuticals Inc's most advanced tracked candidate is bentracimab (Phase 3) for Reversal of antiplatelet activity of ticagrelor in patients with uncontrolled major or life-threatening bleeding or requiring urgent surgery or an invasive procedure.
What is PhaseBio Pharmaceuticals Inc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PhaseBio Pharmaceuticals Inc has approximately 2.6 months of cash runway.
Get the full picture on PhaseBio Pharmaceuticals Inc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.